This covid task order supports niaids need to conduct a trial of an additional dose vaccine to evaluate variant vaccines alone or in combination in an immunologically diverse population. The work…
Ended Awarded Last action
- Contract number
- 75N91022F00007
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $36,854,529
Award facts
- Contract value 100% obligated
- $36,854,529.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Definitize Letter Contract | $14,653,976 | |
| Original award | $22,200,553 |
About this award
This federal contract award, valued at $36,854,529.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract supports NIAID's need to conduct a trial of an additional dose vaccine to evaluate variant vaccines, alone or in combination, in an immunologically diverse population. This work includes the management, oversight, and execution of the clinical trial. The contract is a cost-plus-fixed-fee type with a period of performance through December 31, 2025. The award is not associated with a set-aside designation. Leidos Biomedical Research Inc. has a long history of supporting biomedical research and clinical trials for federal agencies, particularly the National Institutes of Health, and this contract further expands their work on COVID-19 research and vaccine development.
Description
This covid task order supports niaids need to conduct a trial of an additional dose vaccine to evaluate variant vaccines alone or in combination in an immunologically diverse population. The work includes the ability to provide the management, overs
Quick answers
Who was awarded contract 75N91022F00007?
75N91022F00007 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on March 7, 2022.
How much is contract 75N91022F00007 worth?
The government has obligated $36,854,529 on 75N91022F00007.
Which agency awarded contract 75N91022F00007?
National Cancer Institute (National Institutes of Health) awarded 75N91022F00007, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91022F00007 an order under another contract?
Yes. 75N91022F00007 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91022F00007 competed?
The extent of competition for 75N91022F00007 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award